GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » EV-to-Revenue

Delcath Systems (FRA:DV3R) EV-to-Revenue : 64.31 (As of May. 06, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Delcath Systems's enterprise value is €123.22 Mil. Delcath Systems's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €1.92 Mil. Therefore, Delcath Systems's EV-to-Revenue for today is 64.31.

The historical rank and industry rank for Delcath Systems's EV-to-Revenue or its related term are showing as below:

FRA:DV3R' s EV-to-Revenue Range Over the Past 10 Years
Min: -4.74   Med: 10.61   Max: 5448.97
Current: 64.03

During the past 13 years, the highest EV-to-Revenue of Delcath Systems was 5448.97. The lowest was -4.74. And the median was 10.61.

FRA:DV3R's EV-to-Revenue is ranked worse than
94.42% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.22 vs FRA:DV3R: 64.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-06), Delcath Systems's stock price is €5.00. Delcath Systems's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.13. Therefore, Delcath Systems's PS Ratio for today is 38.46.


Delcath Systems EV-to-Revenue Historical Data

The historical data trend for Delcath Systems's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems EV-to-Revenue Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.62 49.71 15.34 16.32 35.07

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.32 14.77 31.94 22.76 35.07

Competitive Comparison of Delcath Systems's EV-to-Revenue

For the Medical Devices subindustry, Delcath Systems's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Delcath Systems's EV-to-Revenue falls into.



Delcath Systems EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Delcath Systems's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=123.224/1.916
=64.31

Delcath Systems's current Enterprise Value is €123.22 Mil.
Delcath Systems's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (FRA:DV3R) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Delcath Systems's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=5.00/0.13
=38.46

Delcath Systems's share price for today is €5.00.
Delcath Systems's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Delcath Systems's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines